Oncofetal HLF transactivates c-Jun to promote hepatocellular carcinoma development and sorafenib resistance - Xiang, Dai-Min; Sun, Wen; Zhou, Tengfei; Zhang, Cheng; Cheng, Zhuo; Li, Shi-Chao; Jiang, Weiqi; Wang, Ruoyu; Fu, Gongbo; Cui, Xiuliang; Hou, Guojun; Jin, Guang-Zhi; et al. (Gut, 2019)
Keywords: Adult; Antineoplastic Agents - pharmacology; Apoptosis; Basic-Leucine Zipper Transcription Factors - biosynthesis; Basic-Leucine Zipper Transcription Factors - genetics; Biomarkers; c-Jun protein; Cancer therapies; carcinogenesis; Carcinoma, Hepatocellular - drug therapy; Carcinoma, Hepatocellular - genetics; Carcinoma, Hepatocellular - pathology; Cell Line, Tumor; Clinical medicine; Disease Progression; DNA, Neoplasm - genetics; drug resistance; Drug Resistance, Neoplasm; Female; Fetuses; Gene expression; Genes, jun - genetics; Hepatocellular carcinoma; Hepatology; Hepatoma; Hospitals; Humans; Immunoprecipitation; Inhibitor drugs; Kinases; Leucine Zippers; Leukemia; Liver cancer; Liver Neoplasms - drug therapy; Liver Neoplasms - genetics; Liver Neoplasms - pathology; Male; Medical diagnosis; Medical prognosis; Oct-4 protein; oncogenes; Patients; Prognosis; Proteins; Signal transduction; Sorafenib - pharmacology; Stem cells; Surgery; Targeted cancer therapy; Therapeutic applications; Transcription factors; Tumors; tumour markers; Xenografts; China; oncogenes; tumour markers; drug resistance; carcinogenesis; hepatocellular carcinoma